Aethlon Medical Reports Q1 FY27 Results; Net Loss $(1.55)M
Aethlon Medical, Inc. announced its financial results for the first fiscal quarter ended June 30, 2026, reporting a net loss attributable to common stockholders of $(1.55) million, an improvement from $(1.76) million in the prior-year quarter. Basic and diluted net loss per share also improved to $(4.02). The company reduced consolidated operating expenses by 11.9% to $1.6 million and reported cash and cash equivalents of $4.9 million. Additionally, Aethlon Medical raised $4.0 million in gross proceeds post-quarter and made significant clinical progress, including dosing the first participant in the final cohort of its Phase 1 oncology study and having a Long COVID manuscript accepted for publication.
Key Highlights
- Net loss attributable to common stockholders decreased to $(1.55) million for Q1 FY27.
- Basic and diluted net loss per share improved to $(4.02) for Q1 FY27.
- Consolidated operating expenses decreased 11.9% to $1.6 million.
- Cash and cash equivalents were approximately $4.9 million as of June 30, 2026.
- Raised approximately $4.0 million in gross proceeds post-quarter through a public offering.
- First participant dosed in the third and final cohort of Phase 1 oncology study in Australia.
- Long COVID manuscript accepted for publication in International Journal of Molecular Sciences.
- Company believes cash resources are sufficient to fund operations for at least the next 12 months.
Price Impact
More from AEMD